Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

he end-user customer.  Cadence recognized this deferred revenue during the period as it determined it had obtained sufficient product return history as of January 1, 2013, to reasonably estimate future wholesaler returns. As a result, the company recorded a one-time adjustment during the three months ended March 31, 2013, to recognize deferred revenue on previously shipped product, resulting in additional net revenue of $2.6 million and cost of sales of $0.9 million, for a net gross margin impact of $1.7 million.

For the three months ended March 31, 2013, Cadence reported a net loss of $1.4 million, or $0.02 per share, compared to a net loss of $22.7 million, or $0.27 per share, for the comparable period in 2012. Included in the company's net loss for the three months ended March 31, 2013, was a gain of $7.7 million Cadence recorded on the waiver, termination and sale of its Incline assets in January 2013, for which the company received cash payments totaling $14.6 million. Excluding the $7.7 million gain from the Incline transaction, and the $1.7 million gross margin impact from the change in the company's revenue recognition accounting estimate, Cadence's net loss for the three months ended March 31, 2013, was $10.8 million, or $0.13 per share.

Gross margin for the three months ended March 31, 2013, was 65%, compared to 47% for the comparable period in 2012. The increase in margin was primarily a result of higher freight costs incurred during the first quarter of 2012 that were not incurred in 2013, the impact of price increases implemented in July 2012 and January 2013, and a one-time credit of $0.3 million recorded during the three months ended March 31, 2013, in connection with the termination of the company's supply agreement with Baxter. Operating expenses, including patent amortization, decreased $2.0 million for the three months ended March 31, 2013, to $23.4 million, from $25.4 million for the same period in 2012. This decrease in
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... (PRWEB) March 04, 2015 USDM ... in the life sciences industry, hired David Blewitt ... the Cloud Compliance Services and Solutions at USDM ... cloud based applications while maintaining compliance with government regulations ... has been an accomplished life sciences regulatory and IS ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 ... in Personalized Medicine, is excited to announce the ... Testing to Optimize the Management of Pain”. , ... at Medscape.com for the next year. The focus ... how to recognize inadequate pain treatments, integrate appropriate ...
(Date:3/4/2015)... , March 4, 2015 ... Paris in December 2011, ... of yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular ... expected late 2016.   SARAH, a large ... cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, ...
(Date:3/3/2015)... astronaut Scott Kelly , who is making final preparations ... and working on the International Space Station, will be available ... Monday, March 9. Kelly will participate from ... of his training. The interviews will be preceded at 5 ... training and previous spaceflights. To schedule an interview, ...
Breaking Biology Technology:USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... 9 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: ... today announced that the Chinese,government has loosened ... throughout China. Aida expects the sales of ... as sales efforts are,pursued nationwide without restriction. ...
... LANSING, Mich., Oct. 9 The Michigan Life ... two new companies designed,to rapidly stimulate significant and ... The Michigan Virtual BioPharma Company, LLC and the ... an exhibit on Tuesday, October,16, 2007, during the ...
... Technology Provides a ,Total Solution, to Orthopedic Imaging, ... announced,that it has received 510k clearance from the Food ... Xray imager in the United States for 2D,imaging use. ... solution to orthopedic imaging,allowing images to be obtained with ...
Cached Biology Technology:Sales of Etimicin Sulfate to Expand Nationwide as Government Restriction is Lifted 2Michigan Life Science Network to Form Two New Virtual Companies 2Michigan Life Science Network to Form Two New Virtual Companies 3FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 2FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 3FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 4
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to ... biometrics technology is to ensure that an individual is who ... technology may make use of a person,s unique physical characteristics, ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a leader ... announced the launch of a TR-FRET (time resolved ... Transcreener UDP Assay, a high throughput screening assay ... assay will allow for sensitive detection of hundreds ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Philadelphia, PA, November 1, 2012 There are a ... are important for the biology of schizophrenia. In a ... Fatj-Vilas and colleagues explored the impact of the interleukin-1β ... Fatj-Vilas said that "this study is a ...
... BiOptix today announced that it would be highlighting the new ... phase-based common path interferometry technology, at the Label Free ... as well as at the PEGS Europe Summit ... Label Free and PEGS Europe meetings, BiOptix will unveil new ...
... by thousands of bacteria and fungi living in ... survive in this diverse environment, plants employ sophisticated ... microorganisms. Here the so-called chitin molecules ... important role as they are detected by the ...
Cached Biology News:Inflammation and cognition in schizophrenia 2BiOptix to highlight new 404pi instrument at European symposia 2Plants recognise pathogenic and beneficial microorganisms 2
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
... with the DeCypher Engine accelerator cards to speed ... searches like these from your desktop: BLAST ... 6 days Align BAC-sized queries (~250 ... analysis to compare 100,000 sequences to PFAM in ...
... tetrasodium bromide), 50mg/vial. MTT is a pale ... cells to yield a dark blue formazan ... even freshly dead cells do not cleave ... a component of Chemicons MTT assay kit, ...
Mouse monoclonal antibody to FMN2 - formin 2...
Biology Products: